L-Annamycin + Cytarabine in Relapsed/Refractory AML

Market
100%75%50%25%0%Apr 13 • YES 32.0%Apr 13Apr 13 • YES 21.1%Apr 13
Trade

Will the results be positive?

Paper Trading
DetailsModel PositionsModel SnapshotsOracle
Details
Primary Completion
8/1/29
Study Completion
8/1/30
Company
Moleculin Biotech, Inc.
Ticker
MBRX
Type
Phase 2/Phase 3
Trial Status
Recruiting
Trial Size
312
Volume
$82.8K
NCT
NCT06788756
Drug Description
Pivotal adaptive Phase 2/Phase 3 randomized, double-blind, placebo-controlled trial of L-Annamycin plus cytarabine in adults with refractory/relapsed AML after one prior line of therapy. Part A selects between two L-Annamycin dose levels using complete remission after one cycle, then Part B expands the chosen regimen against placebo plus cytarabine. The study is recruiting with estimated enrollment of 312 across multiple countries.